Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Amal Therapeutics S.A.

Amal Therapeutics SA is a privately held Swiss biotech company that was incorporated in 2012 as spin-off from the University of Geneva. Under the leadership of Dr. Madiha Derouazi, the company achieved a significant milestone by successfully developing KISIMA, a novel proprietary vaccine technology platform dedicated to oncology indications. *


Period Start 2012-09-01 splitoff
  Group Boehringer Ingelheim (Group)
  Predecessor University of Geneva (Université de Genève, UNIGE)
Products Industry KISIMA technology platform
  Industry 2 ATP124 cancer vaccine (Amal Therapeutics)
Persons Person Derouazi, Madiha (AC Immune 202401–CSO before Speransa Therapeutics + Amal Therapeutics)
  Person 2 Elbers, Knut (Boehringer Ingelheim 201204 Investment Manager + Director Boehringer Ingelheim Venture Fund)
Region Region Genève (Geneva) GE
  Country Switzerland
  Street 64 Avenue de la Roseraie
c/o Fondation pour recherches médicales
  City 1205 Genève GE
  Tel +41-22-379-4688
    Address record changed: 2022-10-29
Basic data Employees B: 11 to 50 (2022-01-01)
    * Document for »About Section«: 
Record changed: 2024-04-04


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x200px

More documents for Boehringer Ingelheim (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top